Abnormal Temporal Slowing on EEG Findings in Preclinical Alzheimer's Disease Patients With the ApoE4 Allele: A Pilot Study
- PMID: 38021568
- PMCID: PMC10679961
- DOI: 10.7759/cureus.47852
Abnormal Temporal Slowing on EEG Findings in Preclinical Alzheimer's Disease Patients With the ApoE4 Allele: A Pilot Study
Abstract
Introduction: Currently, there are limited accessible and cost-effective biomarkers for preclinical Alzheimer's disease (AD) patients. However, the apolipoprotein E (ApoE) polymorphic alleles can predict if someone is at high (e4), neutral (e3), or low (e2) genetic risk for developing AD. This study analyzed electroencephalogram (EEG) reports from individuals with various ApoE genotypes, aiming to identify EEG changes and patterns that could potentially serve as predictive markers for preclinical AD progression.
Methods: Participants aged 64-78 were selected from the patient database at an outpatient neurology clinic. Genotype studies were performed to determine ApoE status, followed by EEG analysis to identify any apparent trends. A case-control design was used, categorizing participants into cases (e2e3, e2e4, e3e4, e4e4) and controls (e3e3). EEG recordings were compared between the groups to identify potential differences in EEG characteristics, including abnormal temporal slowing, frequency, and ApoE genotype association.
Results: Among 43 participants, 49% demonstrated evidence of abnormal temporal slowing on EEG. Of these, 48% displayed focal left temporal slowing, and 52% displayed bilateral temporal slowing. The right-sided temporal slowing was not observed. Among participants with abnormal slowing, 95% exhibited theta frequency (4-8 Hz) slowing, while only 4.8% displayed delta frequency (0-4 Hz) slowing. Among participants with the ApoE4 allele, 61.5% demonstrated evidence of abnormal slowing, compared to 43.3% without it. Furthermore, the presence of an ApoE4 allele was associated with a significantly higher proportion of males (54%) compared to those without it (13%) (p=0.009).
Conclusions: Although we did not find a statistically significant difference in temporal EEG slowing among different ApoE genotypes, our findings suggest a potential association between temporal slowing on EEG and the presence of an ApoE4 allele in individuals with preclinical AD. These observations highlight the need for further exploration into the potential influence of the ApoE4 allele on EEG findings and the utility of EEG as a complementary diagnostic tool for AD. Longitudinal studies with large sample sizes are needed to establish the precise relationship between EEG patterns, ApoE genotypes, and AD progression.
Keywords: alzheimer's disease; apoe4; dementia; electroencephalogram; preclinical; temporal slowing.
Copyright © 2023, Kim et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Genetic association of apolipoprotein E genotype with EEG alpha rhythm slowing and functional brain network alterations during normal aging.Front Neurosci. 2022 Aug 1;16:931173. doi: 10.3389/fnins.2022.931173. eCollection 2022. Front Neurosci. 2022. PMID: 35979332 Free PMC article.
-
APOE effects on regional tau in preclinical Alzheimer's disease.Mol Neurodegener. 2023 Jan 4;18(1):1. doi: 10.1186/s13024-022-00590-4. Mol Neurodegener. 2023. PMID: 36597122 Free PMC article.
-
In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits.Mol Neurobiol. 2018 Aug;55(8):6449-6462. doi: 10.1007/s12035-017-0848-0. Epub 2018 Jan 6. Mol Neurobiol. 2018. PMID: 29307083
-
APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis.Mol Neurobiol. 2019 Apr;56(4):2450-2465. doi: 10.1007/s12035-018-1237-z. Epub 2018 Jul 21. Mol Neurobiol. 2019. PMID: 30032423 Review.
-
Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease.Neurobiol Dis. 2020 May;138:104795. doi: 10.1016/j.nbd.2020.104795. Epub 2020 Feb 6. Neurobiol Dis. 2020. PMID: 32036033 Free PMC article. Review.
Cited by
-
Insights into the role of cerebrospinal fluid cytokines in Alzheimer's disease: A commentary on recent findings.J Alzheimers Dis Rep. 2025 Jun 25;9:25424823251352846. doi: 10.1177/25424823251352846. eCollection 2025 Jan-Dec. J Alzheimers Dis Rep. 2025. PMID: 40575116 Free PMC article.
References
-
- Blank R. Social & Public Policy of Alzheimer's Disease in the United States. Singapore: Palgrave Pivot; 2019. Alzheimer’s disease and other dementias: an introduction.
-
- EEG dynamics in patients with Alzheimer's disease. Jeong J. Clin Neurophysiol. 2004;115:1490–1505. - PubMed
-
- Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E. Arch Neurol. 2010;67:217–223. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous